Tags : mRNA-Based Vaccine

Shots: The ongoing P-I/II study is evaluating the safety, tolerability, and immunogenicity of escalating dose levels of BNT162b1 (10µg & 30µg/ 100 µg) vs PBO in 45 adults aged 18-55yrs. Results: @28days (7days after dose 2), neutralizing GMTs (168 & 267) corresponding to 1.8- and 2.8-times GMT of the convalescent serum panel; elevated RBD-binding IgG […]Read More